BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT

Rhea-AI Summary

BioVaxys Technology Corp. completed the settlement of CAD$215,000 in debt through the issuance of 7,166,666 common shares at a deemed price of $0.03 per common share. The debt did not include accrued salaries to officers or directors, nor payments for Investor Relations Activities. Certain related parties, including BioVaxys CEO James Passin and COO and President Kenneth Kovan, participated in the debt settlement. The securities issued are subject to a four-month hold period from the date of issuance.

VANCOUVER, BC, Jan. 29, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it completed the settlement of CAD$215,000 in debt through the issuance of 7,166,666 common shares issued at a deemed price of $0.03 per common share. None of the debt settled included accrued salaries to officers or directors of the Company, nor does it include payments for Investor Relations Activities. The debt included the participation of certain related parties, including BioVaxys CEO James Passin and BioVaxys COO and President Kenneth Kovan, both of whom are officers of the Company, with James Passin being a director of the Company, and as such it will constitute a "related party transaction" within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company relied on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101.

All securities issued in connection with the completed Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), is a biopharmaceuticals company registered in British Columbia dedicated to improving patient lives with immunotherapeutics based on its HapTenix© 'neoantigen' tumor cell construct platform.  The Company's clinical stage pipeline includes BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'platform, which is planned to enter Phase I in Spain for treating refractive late-stage ovarian cancer.   The Company is also capitalizing on its tumor immunology know-how through creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines and utilize predictive algorithms and other technologies to identify new targetable tumor antigens.  BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).  For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed "James Passin"

James Passin, CEO
+1 646 452 7054

Cautionary Statements Regarding Forward Looking Information

This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved.. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. 

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Logo: https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/biovaxys-announces-completed-debt-settlement-302046638.html

SOURCE BioVaxys Technology Corp.

FAQ

What was the total amount of debt settled by BioVaxys?

BioVaxys settled CAD$215,000 in debt through the issuance of 7,166,666 common shares.

What was the deemed price per common share in the debt settlement?

The deemed price of each common share issued in the debt settlement was $0.03.

Who participated in the debt settlement as related parties?

BioVaxys CEO James Passin and COO and President Kenneth Kovan, both officers of the company, participated in the debt settlement.

Are the securities issued in connection with the debt settlement subject to any hold period?

Yes, all securities issued in connection with the completed Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance.